# Q32 Bio Inc. (QTTB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $11.99, market value $357 million.

## Valuation
- **P/E (trailing): 3.8×** (5-yr avg 1.4×, 3-yr avg 1.4×). Q32 Bio Inc. trades at 3.8× trailing earnings, well above its own five-year average of 1.4×: investors are paying up relative to the company's past. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 6.6×**. Each dollar of revenue is priced at 6.6×.
- **Price / book: 2.7×**. The shares trade at 2.7× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 26.2%**. The inverse of the P/E: 26.2% of the price is earned each year.

## Profitability
- **Operating margin: 31.5%**. 31.5% of revenue is left after running the business, an exceptional level.
- **Net margin: 55.5%**. 55.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 71.0%**. A 71.0% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on assets: 48.3%**. Each dollar of assets produces 48.3% of profit.

## Growth
- **EPS growth (1 yr): 136.8%**. Earnings per share rose 136.8%.

## Financial health
- **Current ratio: 4.85** (quick 4.85). Current assets cover the next year's liabilities 4.85 times.
- **Altman Z-score: 14.41**. A Z-score of 14.41 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Q32 Bio Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (5 analysts). 5 analysts cover Q32 Bio Inc.; the consensus is strong_buy, with an average price target of $41.00 (+242% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 622.3%** (YTD 261.1%, 3-mo -8.5%). The shares are up 622.3% over twelve months including dividends.
- **From 52-week high: -49.1%** (609.5% above the low). Trading 49% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 29**. An RSI of 29 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): -0.28** (volatility 173%). Beta of -0.28 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=QTTB · Page: https://foliofundamentals.com/stocks/qttb

Not investment advice.